Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis
Isoniazid-resistant, rifampicin-susceptible (INH-R) tuberculosis is the most common form of drug resistance, and is associated with failure, relapse, and acquired rifampicin resistance if treated with first-line anti-tuberculosis drugs. The aim of the study was to compare success, mortality, and acq...
Uloženo v:
| Vydáno v: | The lancet respiratory medicine Ročník 6; číslo 4; s. 265 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
01.04.2018
|
| Témata: | |
| ISSN: | 2213-2619, 2213-2619 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Isoniazid-resistant, rifampicin-susceptible (INH-R) tuberculosis is the most common form of drug resistance, and is associated with failure, relapse, and acquired rifampicin resistance if treated with first-line anti-tuberculosis drugs. The aim of the study was to compare success, mortality, and acquired rifampicin resistance in patients with INH-R pulmonary tuberculosis given different durations of rifampicin, ethambutol, and pyrazinamide (REZ); a fluoroquinolone plus 6 months or more of REZ; and streptomycin plus a core regimen of REZ.
Studies with regimens and outcomes known for individual patients with INH-R tuberculosis were eligible, irrespective of the number of patients if randomised trials, or with at least 20 participants if a cohort study. Studies were identified from two relevant systematic reviews, an updated search of one of the systematic reviews (for papers published between April 1, 2015, and Feb 10, 2016), and personal communications. Individual patient data were obtained from authors of eligible studies. The individual patient data meta-analysis was performed with propensity score matched logistic regression to estimate adjusted odds ratios (aOR) and risk differences of treatment success (cure or treatment completion), death during treatment, and acquired rifampicin resistance. Outcomes were measured across different treatment regimens to assess the effects of: different durations of REZ (≤6 months vs >6 months); addition of a fluoroquinolone to REZ (fluoroquinolone plus 6 months or more of REZ vs 6 months or more of REZ); and addition of streptomycin to REZ (streptomycin plus 6 months of rifampicin and ethambutol and 1-3 months of pyrazinamide vs 6 months or more of REZ). The overall quality of the evidence was assessed using GRADE methodology.
Individual patient data were requested for 57 cohort studies and 17 randomised trials including 8089 patients with INH-R tuberculosis. We received 33 datasets with 6424 patients, of which 3923 patients in 23 studies received regimens related to the study objectives. Compared with a daily regimen of 6 months of (H)REZ (REZ with or without isoniazid), extending the duration to 8-9 months had similar outcomes; as such, 6 months or more of (H)REZ was used for subsequent comparisons. Addition of a fluoroquinolone to 6 months or more of (H)REZ was associated with significantly greater treatment success (aOR 2·8, 95% CI 1·1-7·3), but no significant effect on mortality (aOR 0·7, 0·4-1·1) or acquired rifampicin resistance (aOR 0·1, 0·0-1·2). Compared with 6 months or more of (H)REZ, the standardised retreatment regimen (2 months of streptomycin, 3 months of pyrazinamide, and 8 months of isoniazid, rifampicin, and ethambutol) was associated with significantly worse treatment success (aOR 0·4, 0·2-0·7). The quality of the evidence was very low for all outcomes and treatment regimens assessed, owing to the observational nature of most of the data, the diverse settings, and the imprecision of estimates.
In patients with INH-R tuberculosis, compared with treatment with at least 6 months of daily REZ, addition of a fluoroquinolone was associated with better treatment success, whereas addition of streptomycin was associated with less treatment success; however, the quality of the evidence was very low. These results support the conduct of randomised trials to identify the optimum regimen for this important and common form of drug-resistant tuberculosis.
World Health Organization and Canadian Institutes of Health Research. |
|---|---|
| AbstractList | Isoniazid-resistant, rifampicin-susceptible (INH-R) tuberculosis is the most common form of drug resistance, and is associated with failure, relapse, and acquired rifampicin resistance if treated with first-line anti-tuberculosis drugs. The aim of the study was to compare success, mortality, and acquired rifampicin resistance in patients with INH-R pulmonary tuberculosis given different durations of rifampicin, ethambutol, and pyrazinamide (REZ); a fluoroquinolone plus 6 months or more of REZ; and streptomycin plus a core regimen of REZ.
Studies with regimens and outcomes known for individual patients with INH-R tuberculosis were eligible, irrespective of the number of patients if randomised trials, or with at least 20 participants if a cohort study. Studies were identified from two relevant systematic reviews, an updated search of one of the systematic reviews (for papers published between April 1, 2015, and Feb 10, 2016), and personal communications. Individual patient data were obtained from authors of eligible studies. The individual patient data meta-analysis was performed with propensity score matched logistic regression to estimate adjusted odds ratios (aOR) and risk differences of treatment success (cure or treatment completion), death during treatment, and acquired rifampicin resistance. Outcomes were measured across different treatment regimens to assess the effects of: different durations of REZ (≤6 months vs >6 months); addition of a fluoroquinolone to REZ (fluoroquinolone plus 6 months or more of REZ vs 6 months or more of REZ); and addition of streptomycin to REZ (streptomycin plus 6 months of rifampicin and ethambutol and 1-3 months of pyrazinamide vs 6 months or more of REZ). The overall quality of the evidence was assessed using GRADE methodology.
Individual patient data were requested for 57 cohort studies and 17 randomised trials including 8089 patients with INH-R tuberculosis. We received 33 datasets with 6424 patients, of which 3923 patients in 23 studies received regimens related to the study objectives. Compared with a daily regimen of 6 months of (H)REZ (REZ with or without isoniazid), extending the duration to 8-9 months had similar outcomes; as such, 6 months or more of (H)REZ was used for subsequent comparisons. Addition of a fluoroquinolone to 6 months or more of (H)REZ was associated with significantly greater treatment success (aOR 2·8, 95% CI 1·1-7·3), but no significant effect on mortality (aOR 0·7, 0·4-1·1) or acquired rifampicin resistance (aOR 0·1, 0·0-1·2). Compared with 6 months or more of (H)REZ, the standardised retreatment regimen (2 months of streptomycin, 3 months of pyrazinamide, and 8 months of isoniazid, rifampicin, and ethambutol) was associated with significantly worse treatment success (aOR 0·4, 0·2-0·7). The quality of the evidence was very low for all outcomes and treatment regimens assessed, owing to the observational nature of most of the data, the diverse settings, and the imprecision of estimates.
In patients with INH-R tuberculosis, compared with treatment with at least 6 months of daily REZ, addition of a fluoroquinolone was associated with better treatment success, whereas addition of streptomycin was associated with less treatment success; however, the quality of the evidence was very low. These results support the conduct of randomised trials to identify the optimum regimen for this important and common form of drug-resistant tuberculosis.
World Health Organization and Canadian Institutes of Health Research. Isoniazid-resistant, rifampicin-susceptible (INH-R) tuberculosis is the most common form of drug resistance, and is associated with failure, relapse, and acquired rifampicin resistance if treated with first-line anti-tuberculosis drugs. The aim of the study was to compare success, mortality, and acquired rifampicin resistance in patients with INH-R pulmonary tuberculosis given different durations of rifampicin, ethambutol, and pyrazinamide (REZ); a fluoroquinolone plus 6 months or more of REZ; and streptomycin plus a core regimen of REZ.BACKGROUNDIsoniazid-resistant, rifampicin-susceptible (INH-R) tuberculosis is the most common form of drug resistance, and is associated with failure, relapse, and acquired rifampicin resistance if treated with first-line anti-tuberculosis drugs. The aim of the study was to compare success, mortality, and acquired rifampicin resistance in patients with INH-R pulmonary tuberculosis given different durations of rifampicin, ethambutol, and pyrazinamide (REZ); a fluoroquinolone plus 6 months or more of REZ; and streptomycin plus a core regimen of REZ.Studies with regimens and outcomes known for individual patients with INH-R tuberculosis were eligible, irrespective of the number of patients if randomised trials, or with at least 20 participants if a cohort study. Studies were identified from two relevant systematic reviews, an updated search of one of the systematic reviews (for papers published between April 1, 2015, and Feb 10, 2016), and personal communications. Individual patient data were obtained from authors of eligible studies. The individual patient data meta-analysis was performed with propensity score matched logistic regression to estimate adjusted odds ratios (aOR) and risk differences of treatment success (cure or treatment completion), death during treatment, and acquired rifampicin resistance. Outcomes were measured across different treatment regimens to assess the effects of: different durations of REZ (≤6 months vs >6 months); addition of a fluoroquinolone to REZ (fluoroquinolone plus 6 months or more of REZ vs 6 months or more of REZ); and addition of streptomycin to REZ (streptomycin plus 6 months of rifampicin and ethambutol and 1-3 months of pyrazinamide vs 6 months or more of REZ). The overall quality of the evidence was assessed using GRADE methodology.METHODSStudies with regimens and outcomes known for individual patients with INH-R tuberculosis were eligible, irrespective of the number of patients if randomised trials, or with at least 20 participants if a cohort study. Studies were identified from two relevant systematic reviews, an updated search of one of the systematic reviews (for papers published between April 1, 2015, and Feb 10, 2016), and personal communications. Individual patient data were obtained from authors of eligible studies. The individual patient data meta-analysis was performed with propensity score matched logistic regression to estimate adjusted odds ratios (aOR) and risk differences of treatment success (cure or treatment completion), death during treatment, and acquired rifampicin resistance. Outcomes were measured across different treatment regimens to assess the effects of: different durations of REZ (≤6 months vs >6 months); addition of a fluoroquinolone to REZ (fluoroquinolone plus 6 months or more of REZ vs 6 months or more of REZ); and addition of streptomycin to REZ (streptomycin plus 6 months of rifampicin and ethambutol and 1-3 months of pyrazinamide vs 6 months or more of REZ). The overall quality of the evidence was assessed using GRADE methodology.Individual patient data were requested for 57 cohort studies and 17 randomised trials including 8089 patients with INH-R tuberculosis. We received 33 datasets with 6424 patients, of which 3923 patients in 23 studies received regimens related to the study objectives. Compared with a daily regimen of 6 months of (H)REZ (REZ with or without isoniazid), extending the duration to 8-9 months had similar outcomes; as such, 6 months or more of (H)REZ was used for subsequent comparisons. Addition of a fluoroquinolone to 6 months or more of (H)REZ was associated with significantly greater treatment success (aOR 2·8, 95% CI 1·1-7·3), but no significant effect on mortality (aOR 0·7, 0·4-1·1) or acquired rifampicin resistance (aOR 0·1, 0·0-1·2). Compared with 6 months or more of (H)REZ, the standardised retreatment regimen (2 months of streptomycin, 3 months of pyrazinamide, and 8 months of isoniazid, rifampicin, and ethambutol) was associated with significantly worse treatment success (aOR 0·4, 0·2-0·7). The quality of the evidence was very low for all outcomes and treatment regimens assessed, owing to the observational nature of most of the data, the diverse settings, and the imprecision of estimates.FINDINGSIndividual patient data were requested for 57 cohort studies and 17 randomised trials including 8089 patients with INH-R tuberculosis. We received 33 datasets with 6424 patients, of which 3923 patients in 23 studies received regimens related to the study objectives. Compared with a daily regimen of 6 months of (H)REZ (REZ with or without isoniazid), extending the duration to 8-9 months had similar outcomes; as such, 6 months or more of (H)REZ was used for subsequent comparisons. Addition of a fluoroquinolone to 6 months or more of (H)REZ was associated with significantly greater treatment success (aOR 2·8, 95% CI 1·1-7·3), but no significant effect on mortality (aOR 0·7, 0·4-1·1) or acquired rifampicin resistance (aOR 0·1, 0·0-1·2). Compared with 6 months or more of (H)REZ, the standardised retreatment regimen (2 months of streptomycin, 3 months of pyrazinamide, and 8 months of isoniazid, rifampicin, and ethambutol) was associated with significantly worse treatment success (aOR 0·4, 0·2-0·7). The quality of the evidence was very low for all outcomes and treatment regimens assessed, owing to the observational nature of most of the data, the diverse settings, and the imprecision of estimates.In patients with INH-R tuberculosis, compared with treatment with at least 6 months of daily REZ, addition of a fluoroquinolone was associated with better treatment success, whereas addition of streptomycin was associated with less treatment success; however, the quality of the evidence was very low. These results support the conduct of randomised trials to identify the optimum regimen for this important and common form of drug-resistant tuberculosis.INTERPRETATIONIn patients with INH-R tuberculosis, compared with treatment with at least 6 months of daily REZ, addition of a fluoroquinolone was associated with better treatment success, whereas addition of streptomycin was associated with less treatment success; however, the quality of the evidence was very low. These results support the conduct of randomised trials to identify the optimum regimen for this important and common form of drug-resistant tuberculosis.World Health Organization and Canadian Institutes of Health Research.FUNDINGWorld Health Organization and Canadian Institutes of Health Research. |
| Author | Bastos, Mayara Garcia-Prats, Anthony J Nguyen, Viet Nhung Trieu, Lisa Falzon, Dennis Skrahina, Alena Glynn, Judith R Bang, Didi Johnston, James C Akkerman, Onno W Cegielski, Peter Wang, Jann-Yuan Benedetti, Andrea Schaaf, H Simon Arakaki-Sanchez, Denise Lan, Zhi Yi Phillips, Patrick P J Viiklepp, Piret Escalante, Patricio Koh, Won-Jung Tabarsi, Payam Bonnet, Maryline Trajman, Anete Li, Pei Zhi Chien, Jung-Yien Ohkado, Akihiro Reves, Randall Romanowski, Kamila Gillespie, Stephen H Jacobson, Karen R Fregonese, Federica Gegia, Medea Cox, Helen Merle, Corinne S C Munang, Melinda Goldberg, Stefan Menzies, Dick Kritski, Afranio Park, Jong Sun Soolingen, Dick van Erkens, Connie Galliez, Rafael Mello Khan, Awal Nunn, Andrew Griffith, David Dedicoat, Martin Lee, Jae Ho Yoshiyama, Takashi Banurekha, Velayutham V Ayakaka, Irene Baghaei, Parvaneh Jones-López, Edward C Narendran, Gopalan Seung, Kwonjune Maciel, Ethel L Ponnuraja, Chinnaiyan Ahuja, Shama D Cattamanchi, Adithya |
| Author_xml | – sequence: 1 givenname: Federica surname: Fregonese fullname: Fregonese, Federica organization: Montreal Chest Institute, McGill University Health Center Research Institute, McGill University, Montreal, Canada – sequence: 2 givenname: Shama D surname: Ahuja fullname: Ahuja, Shama D organization: Bureau of Tuberculosis Control, New York City Department of Health and Mental Hygiene, Queens, NY, USA – sequence: 3 givenname: Onno W surname: Akkerman fullname: Akkerman, Onno W organization: University Medical Centre Groningen, Department of Pulmonary Diseases and Tuberculosis, University of Groningen, Groningen, Netherlands – sequence: 4 givenname: Denise surname: Arakaki-Sanchez fullname: Arakaki-Sanchez, Denise organization: National Tuberculosis Control Program, Brasilia, Brazil – sequence: 5 givenname: Irene surname: Ayakaka fullname: Ayakaka, Irene organization: Uganda Tuberculosis Research Consortium, Kampala, Uganda – sequence: 6 givenname: Parvaneh surname: Baghaei fullname: Baghaei, Parvaneh organization: Clinical Tuberculosis and Epidemiology Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran – sequence: 7 givenname: Didi surname: Bang fullname: Bang, Didi organization: Statens Serum Institut, Copenhagen, Denmark – sequence: 8 givenname: Mayara surname: Bastos fullname: Bastos, Mayara organization: Epidemiology Department, Social Medicine Institute, University of Rio de Janeiro, Brazil – sequence: 9 givenname: Andrea surname: Benedetti fullname: Benedetti, Andrea organization: Montreal Chest Institute, McGill University Health Center Research Institute, McGill University, Montreal, Canada; Department of Epidemiology, Biostatistics & Occupational Health, McGill University, Montreal, Canada – sequence: 10 givenname: Maryline surname: Bonnet fullname: Bonnet, Maryline organization: Institut de Recherche pour le Développement UM233, INSERM U1175, Université de Montpellier, Montpellier, France; Epicentre MSF, Paris, France – sequence: 11 givenname: Adithya surname: Cattamanchi fullname: Cattamanchi, Adithya organization: Division of Pulmonary and Critical Care Medicine and Curry International Tuberculosis Center, University of California San Francisco, San Francisco, CA, USA – sequence: 12 givenname: Peter surname: Cegielski fullname: Cegielski, Peter organization: Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA – sequence: 13 givenname: Jung-Yien surname: Chien fullname: Chien, Jung-Yien organization: Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan – sequence: 14 givenname: Helen surname: Cox fullname: Cox, Helen organization: Division of Medical Microbiology and Institute of Infectious Diseases and Molecular Medicine University of Cape Town, Cape Town, South Africa – sequence: 15 givenname: Martin surname: Dedicoat fullname: Dedicoat, Martin organization: Heart of England NHS Foundation Trust, Birmingham, UK – sequence: 16 givenname: Connie surname: Erkens fullname: Erkens, Connie organization: KNCV Tuberculosis Foundation, Team The Netherlands and Elimination, The Hague, Netherlands – sequence: 17 givenname: Patricio surname: Escalante fullname: Escalante, Patricio organization: Division of Pulmonary and Critical Care Medicine, Department of Medicine, and Mayo Clinic Center for Tuberculosis, Mayo Clinic, Rochester, USA – sequence: 18 givenname: Dennis surname: Falzon fullname: Falzon, Dennis organization: Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland – sequence: 19 givenname: Anthony J surname: Garcia-Prats fullname: Garcia-Prats, Anthony J organization: Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa – sequence: 20 givenname: Medea surname: Gegia fullname: Gegia, Medea organization: Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland – sequence: 21 givenname: Stephen H surname: Gillespie fullname: Gillespie, Stephen H organization: School of Medicine, University of St Andrews North Haugh, St Andrews, UK – sequence: 22 givenname: Judith R surname: Glynn fullname: Glynn, Judith R organization: Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK – sequence: 23 givenname: Stefan surname: Goldberg fullname: Goldberg, Stefan organization: Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA – sequence: 24 givenname: David surname: Griffith fullname: Griffith, David organization: The University of Texas Health Science Center, Tyler, TX, USA – sequence: 25 givenname: Karen R surname: Jacobson fullname: Jacobson, Karen R organization: Section of Infectious Diseases, Department of Medicine Boston University School of Medicine and Boston Medical Center, Boston, MA, USA – sequence: 26 givenname: James C surname: Johnston fullname: Johnston, James C organization: Department of Medicine, University of British Columbia, Vancouver, BC, Canada; British Columbia Centre for Disease Control, Vancouver, BC, Canada – sequence: 27 givenname: Edward C surname: Jones-López fullname: Jones-López, Edward C organization: Section of Infectious Diseases, Department of Medicine Boston University School of Medicine and Boston Medical Center, Boston, MA, USA – sequence: 28 givenname: Awal surname: Khan fullname: Khan, Awal organization: Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA – sequence: 29 givenname: Won-Jung surname: Koh fullname: Koh, Won-Jung organization: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea – sequence: 30 givenname: Afranio surname: Kritski fullname: Kritski, Afranio organization: Academic Tuberculosis Program, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil – sequence: 31 givenname: Zhi Yi surname: Lan fullname: Lan, Zhi Yi organization: Montreal Chest Institute, McGill University Health Center Research Institute, McGill University, Montreal, Canada; Department of Epidemiology, Biostatistics & Occupational Health, McGill University, Montreal, Canada – sequence: 32 givenname: Jae Ho surname: Lee fullname: Lee, Jae Ho organization: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul, South Korea – sequence: 33 givenname: Pei Zhi surname: Li fullname: Li, Pei Zhi organization: Montreal Chest Institute, McGill University Health Center Research Institute, McGill University, Montreal, Canada – sequence: 34 givenname: Ethel L surname: Maciel fullname: Maciel, Ethel L organization: Laboratory of Epidemiology, Federal University of Espirito Santo, Espírito Santo, Brazil – sequence: 35 givenname: Rafael Mello surname: Galliez fullname: Galliez, Rafael Mello organization: State Institute of Infectology São Sebastião, Center for Research and Tuberculosis, Faculty of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil – sequence: 36 givenname: Corinne S C surname: Merle fullname: Merle, Corinne S C organization: Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, Switzerland; Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK – sequence: 37 givenname: Melinda surname: Munang fullname: Munang, Melinda organization: Heart of England NHS Foundation Trust, Birmingham, UK – sequence: 38 givenname: Gopalan surname: Narendran fullname: Narendran, Gopalan organization: Department of Clinical Research, The National Institute for Research in Tuberculosis, Chennai, India – sequence: 39 givenname: Viet Nhung surname: Nguyen fullname: Nguyen, Viet Nhung organization: National Lung Hospital, Ba Dinh, Hanoi, Vietnam; Hanoi Medical University, Hanoi, Vietnam – sequence: 40 givenname: Andrew surname: Nunn fullname: Nunn, Andrew organization: Medical Research Council UK Clinical Trials Unit, University College London, London, UK – sequence: 41 givenname: Akihiro surname: Ohkado fullname: Ohkado, Akihiro organization: Department of Epidemiology and Clinical Research, the Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan; Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan – sequence: 42 givenname: Jong Sun surname: Park fullname: Park, Jong Sun organization: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul, South Korea – sequence: 43 givenname: Patrick P J surname: Phillips fullname: Phillips, Patrick P J organization: Division of Pulmonary & Critical Medicine, University of California San Francisco, San Francisco, CA, USA – sequence: 44 givenname: Chinnaiyan surname: Ponnuraja fullname: Ponnuraja, Chinnaiyan organization: The National Institute for Research in Tuberculosis, Chetpet, India – sequence: 45 givenname: Randall surname: Reves fullname: Reves, Randall organization: Denver Public Health Department, Denver, CO, USA – sequence: 46 givenname: Kamila surname: Romanowski fullname: Romanowski, Kamila organization: British Columbia Centre for Disease Control, Vancouver, BC, Canada – sequence: 47 givenname: Kwonjune surname: Seung fullname: Seung, Kwonjune organization: Partners in Health, Boston, MA, USA – sequence: 48 givenname: H Simon surname: Schaaf fullname: Schaaf, H Simon organization: Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa – sequence: 49 givenname: Alena surname: Skrahina fullname: Skrahina, Alena organization: Republican Scientific and Practical Centre of Pulmonology and Tuberculosis, Ministry of Health, Minsk, Belarus – sequence: 50 givenname: Dick van surname: Soolingen fullname: Soolingen, Dick van organization: National Tuberculosis Reference Laboratory, National Institute for Public Health and the Environment, Bilthoven, Netherlands – sequence: 51 givenname: Payam surname: Tabarsi fullname: Tabarsi, Payam organization: Clinical Tuberculosis and Epidemiology Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran – sequence: 52 givenname: Anete surname: Trajman fullname: Trajman, Anete organization: Montreal Chest Institute, McGill University Health Center Research Institute, McGill University, Montreal, Canada; Epidemiology Department, Social Medicine Institute, University of Rio de Janeiro, Brazil – sequence: 53 givenname: Lisa surname: Trieu fullname: Trieu, Lisa organization: Bureau of Tuberculosis Control, New York City Department of Health and Mental Hygiene, Queens, NY, USA – sequence: 54 givenname: Velayutham V surname: Banurekha fullname: Banurekha, Velayutham V organization: Department of Clinical Research, The National Institute for Research in Tuberculosis, Chennai, India – sequence: 55 givenname: Piret surname: Viiklepp fullname: Viiklepp, Piret organization: Estonian Tuberculosis Registry, National Institute for Health Development, Tallinn, Estonia – sequence: 56 givenname: Jann-Yuan surname: Wang fullname: Wang, Jann-Yuan organization: Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan – sequence: 57 givenname: Takashi surname: Yoshiyama fullname: Yoshiyama, Takashi organization: Research Institute of Tuberculosis, Tokyo, Japan – sequence: 58 givenname: Dick surname: Menzies fullname: Menzies, Dick email: dick.menzies@mcgill.ca organization: Montreal Chest Institute, McGill University Health Center Research Institute, McGill University, Montreal, Canada. Electronic address: dick.menzies@mcgill.ca |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29595509$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkE1LxDAYhIOsuLruT1ByXA_VJP1KvcniFyx4UMFbeZO8hUibdpNUWH-9XVzBucwwPMxhzsjM9Q4JueDsmjNe3LwKwdNEFIytuLxKGStl8nFETg81r2b_8pwsQ_hkk6TMBMtOyFxUeZXnrDol23XfDeBt6B3tG2ps06BHF2n0CLGbUqBN7-kesPBtTeIx2BBhj4wKvR7bfipuKThqnbFf1ozQ0gGi3c8YiEA7jJCAg3Y3kefkuIE24PLgC_L-cP-2fko2L4_P67tNootMxERzpbRGrasMhVRoGikRoeSqkqnQQrEyb0pldKqQCZheqSAzqslQC8NYIRZk9bs7-H47Yoh1Z4PGtgWH_RhqwXglmRSlnNDLAzqqDk09eNuB39V_N4kfBVhxWA |
| CitedBy_id | crossref_primary_10_3389_fmed_2025_1596579 crossref_primary_10_1016_j_jmii_2025_08_012 crossref_primary_10_1055_a_1934_8303 crossref_primary_10_1128_aac_01829_21 crossref_primary_10_1016_j_rmed_2020_106163 crossref_primary_10_1186_s13756_019_0561_z crossref_primary_10_1016_j_idc_2019_09_002 crossref_primary_10_1016_j_arbr_2018_10_014 crossref_primary_10_1016_j_tube_2023_102367 crossref_primary_10_1513_AnnalsATS_202004_318CME crossref_primary_10_1371_journal_pone_0229691 crossref_primary_10_4103_ijmr_ijmr_677_22 crossref_primary_10_1016_j_arbres_2018_10_014 crossref_primary_10_3390_medicina59020246 crossref_primary_10_1016_j_jgar_2020_07_012 crossref_primary_10_1016_S2213_2600_18_30209_1 crossref_primary_10_1016_S1473_3099_22_00875_1 crossref_primary_10_1016_j_cmi_2023_07_013 crossref_primary_10_1016_j_mmifmc_2022_02_001 crossref_primary_10_1016_j_cmi_2024_09_027 crossref_primary_10_1016_S0140_6736_19_31882_3 crossref_primary_10_1513_AnnalsATS_202312_1076OC crossref_primary_10_1080_24745332_2022_2039499 crossref_primary_10_1371_journal_pone_0233500 crossref_primary_10_1186_s12879_022_07067_1 crossref_primary_10_1016_j_rmed_2018_12_001 crossref_primary_10_1183_13993003_00982_2019 crossref_primary_10_1016_j_ijid_2023_05_002 crossref_primary_10_1016_j_pcl_2021_09_004 crossref_primary_10_4103_lungindia_lungindia_221_23 crossref_primary_10_1016_S2213_2600_19_30366_2 crossref_primary_10_3201_eid2603_190997 crossref_primary_10_1080_14656566_2021_1967930 crossref_primary_10_3390_ijerph18062965 crossref_primary_10_1038_s41572_024_00504_2 crossref_primary_10_1093_ofid_ofaf398 crossref_primary_10_1080_24745332_2023_2226006 crossref_primary_10_1016_S0140_6736_24_02479_6 crossref_primary_10_1016_j_arbr_2020_03_014 crossref_primary_10_1080_14787210_2023_2207820 crossref_primary_10_1097_PHH_0000000000001060 crossref_primary_10_1128_cmr_00180_19 crossref_primary_10_1183_13993003_01494_2019 crossref_primary_10_1093_ofid_ofaa300 crossref_primary_10_3389_fimmu_2022_1027472 crossref_primary_10_1016_S2213_2600_18_30079_1 crossref_primary_10_1016_j_ijregi_2022_09_005 crossref_primary_10_1128_aac_00357_24 crossref_primary_10_5588_ijtldopen_23_0533 crossref_primary_10_1371_journal_pmed_1003023 crossref_primary_10_35366_95650 crossref_primary_10_1016_j_arbres_2020_03_021 crossref_primary_10_2217_fmb_2020_0089 crossref_primary_10_3201_eid2809_220092 crossref_primary_10_1371_journal_pone_0246993 crossref_primary_10_1093_ofid_ofz222 crossref_primary_10_3390_pathogens12121439 crossref_primary_10_1371_journal_pone_0211355 crossref_primary_10_3389_fmed_2023_1085010 crossref_primary_10_1016_j_ijtb_2020_11_010 crossref_primary_10_1080_22221751_2024_2417855 crossref_primary_10_1164_rccm_201909_1874ST crossref_primary_10_2147_IDR_S420830 crossref_primary_10_1016_j_ccm_2019_08_002 crossref_primary_10_1080_17476348_2021_1828069 crossref_primary_10_1128_AAC_00384_19 crossref_primary_10_1016_j_medcle_2024_02_016 crossref_primary_10_1016_j_jgar_2025_02_003 crossref_primary_10_1371_journal_pone_0273263 crossref_primary_10_4103_amit_amit_91_23 crossref_primary_10_1371_journal_pone_0281638 |
| ContentType | Journal Article |
| Copyright | Copyright © 2018 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. Published by Elsevier Ltd.. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2018 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. Published by Elsevier Ltd.. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/S2213-2600(18)30078-X |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2213-2619 |
| ExternalDocumentID | 29595509 |
| Genre | Meta-Analysis Comparative Study Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation | World Health Organization and Canadian Institutes of Health Research. |
| GrantInformation_xml | – fundername: Intramural CDC HHS grantid: CC999999 – fundername: CIHR – fundername: World Health Organization grantid: 001 |
| GroupedDBID | .1- .FO 0R~ 1P~ 4.4 457 53G AAEDT AAEDW AALRI AAMRU AAQFI AAQQT AAXUO ABJNI ACGFS ADBBV AENEX AFRHN AFTJW AGCQF AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP CGR CUY CVF EBS ECM EFKBS EIF EJD FDB HZ~ M41 NPM O9- OI- OU. ROL TLN Z5R 7X8 |
| ID | FETCH-LOGICAL-c642t-c1bbccecc94e28bedf88eea71b9832c2b075f7bdc3be02a0169a4dbf4ec2d0062 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 78 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000428231000024&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2213-2619 |
| IngestDate | Thu Oct 02 03:42:03 EDT 2025 Mon Jul 21 06:05:45 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| License | Copyright © 2018 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. Published by Elsevier Ltd.. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c642t-c1bbccecc94e28bedf88eea71b9832c2b075f7bdc3be02a0169a4dbf4ec2d0062 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/9017096 |
| PMID | 29595509 |
| PQID | 2019808278 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2019808278 pubmed_primary_29595509 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-04-01 |
| PublicationDateYYYYMMDD | 2018-04-01 |
| PublicationDate_xml | – month: 04 year: 2018 text: 2018-04-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | The lancet respiratory medicine |
| PublicationTitleAlternate | Lancet Respir Med |
| PublicationYear | 2018 |
| References | 29595499 - Lancet Respir Med. 2018 Apr;6(4):233-235. doi: 10.1016/S2213-2600(18)30079-1. 29680638 - Lancet Respir Med. 2018 Jun;6(6):e27. doi: 10.1016/S2213-2600(18)30174-7. 29976445 - Lancet Respir Med. 2018 Jul;6(7):e29. doi: 10.1016/S2213-2600(18)30209-1. |
| References_xml | – reference: 29680638 - Lancet Respir Med. 2018 Jun;6(6):e27. doi: 10.1016/S2213-2600(18)30174-7. – reference: 29976445 - Lancet Respir Med. 2018 Jul;6(7):e29. doi: 10.1016/S2213-2600(18)30209-1. – reference: 29595499 - Lancet Respir Med. 2018 Apr;6(4):233-235. doi: 10.1016/S2213-2600(18)30079-1. |
| SSID | ssj0000884204 |
| Score | 2.4690268 |
| SecondaryResourceType | review_article |
| Snippet | Isoniazid-resistant, rifampicin-susceptible (INH-R) tuberculosis is the most common form of drug resistance, and is associated with failure, relapse, and... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 265 |
| SubjectTerms | Antibiotics, Antitubercular - administration & dosage Cohort Studies Drug Administration Schedule Drug Therapy, Combination Ethambutol - administration & dosage Fluoroquinolones - administration & dosage Humans Observational Studies as Topic Outcome Assessment, Health Care Pyrazinamide - administration & dosage Randomized Controlled Trials as Topic Review Literature as Topic Rifampin - administration & dosage Streptomycin - administration & dosage Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - mortality |
| Title | Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29595509 https://www.proquest.com/docview/2019808278 |
| Volume | 6 |
| WOSCitedRecordID | wos000428231000024&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA5qRbz4ftQXETzoIbibpM2uF5Fi8dJSUGFvS55Q0N2223rw1zvppu1JELwsbMjCkkxm5ss8PoRupDRKtVxEhFUp4Uy2SCoMI0ZKJ61pR5bVZBOi30-yLB2EC7cqpFUudOJcUZtS-ztyAOkAj8FeieRxNCaeNcpHVwOFxjpqMHBlvFSLLFnescAJ4nTOIEhpzIgHC6sinvvXMBhFt3Fyx7yxJNnvjubc4HR3__ure2gnuJr4qZaNfbRmiwO01QvB9EM07iw5CHHp8IIqZYqXyecVBpcW-wlD-T00BKC5dzf9lJmyEz37KGHgAcsCD5eFXTi0asU--RR_2qkkMnQ-OULv3ee3zgsJDAxEAy6ZEh0rpTXscsotTZQ1LkmslSJWKWgCTRU4HE4oo5myEZW-s4vkRjluNTW-PPMYbRRlYU8R5qrNjYlMmznFhWmBkDAqdOx8_30buya6XixmDhLuwxaysOWsylfL2UQn9Y7ko7oVR07TVgoYKz37w9fnaBtekjrt5gI1HJxve4k29dd0WE2u5qIDz_6g9wM_ItHr |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+different+treatments+for+isoniazid-resistant+tuberculosis%3A+an+individual+patient+data+meta-analysis&rft.jtitle=The+lancet+respiratory+medicine&rft.au=Fregonese%2C+Federica&rft.au=Ahuja%2C+Shama+D&rft.au=Akkerman%2C+Onno+W&rft.au=Arakaki-Sanchez%2C+Denise&rft.date=2018-04-01&rft.eissn=2213-2619&rft.volume=6&rft.issue=4&rft.spage=265&rft_id=info:doi/10.1016%2FS2213-2600%2818%2930078-X&rft_id=info%3Apmid%2F29595509&rft_id=info%3Apmid%2F29595509&rft.externalDocID=29595509 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2213-2619&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2213-2619&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2213-2619&client=summon |